Share on LinkedInShare on LinkedIn

ARTICLE · 08 SEPTEMBER 2015

Compulsory licences now available for export of patented pharmaceuticals to developing companies

The TRIPS Agreement sets out the minimum requirements for intellectual property protection for WTO member states.

AustraliaIntellectual Property

As of 25 August 2015, it is now possible for third parties to apply to the Federal Court of Australia for a compulsory licence to manufacture generic versions of patented pharmaceutical inventions ("PPI") for export to developing countries to address public health problems.

Background

Australia is a signatory to the World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (the TRIPS Agreement). The TRIPS Agreement sets out the minimum requirements for intellectual property protection for WTO member states.

The TRIPS Agreement was amended in 2005 by the TRIPS Protocol, which had the aim of providing developing countries with better access to medicines. Under the TRIPS Protocol, WTO member states with insufficient manufacturing capacity are able to import patented pharmaceutical products made under a compulsory licence from another WTO member state.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from